Latest Capital Raises News

Island Pharmaceuticals reports a 213.8% increase in half-year loss to $4.81 million, driven by strategic acquisition and clinical development investments. The company advances its antiviral portfolio with Galidesivir and ISLA-101, supported by strong US regulatory engagement and a $9 million capital raise.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Global Health Limited reports a modest half-year loss reduction alongside a steady rise in recurring SaaS revenue, signaling progress in its digital healthcare transformation.

RocketDNA Ltd reported a 6% increase in revenue to AUD 76.83 million for the year ended 31 December 2025, expanding its autonomous drone footprint across Australia and Africa while securing major mining contracts.

HITIQ Limited reported a $2.9 million loss for the half-year ending December 2025, while making significant strides in international market expansion and strategic partnerships. The company’s capital raising efforts aim to support its transition from technology validation to commercial execution.

Carnegie Clean Energy reported a $1.7 million loss for the half-year ending December 2025, while pushing forward with key wave energy projects and securing $2.1 million in fresh capital.

Anatara Lifesciences reports a significantly reduced net loss for H1 FY2026, driven by promising pre-clinical results in its anti-obesity program and a successful $1.2 million capital raise. The company also highlights positive Phase II trial outcomes for its gastrointestinal health product GaRP.

Stealth Group Holdings has delivered record half-year results for 1H26, boosted by its strategic acquisition of Hardware & Building Traders and a strengthened balance sheet. The company is now targeting over $500 million in sales by FY28, signalling ambitious growth in Australia's fragmented hardware and industrial distribution market.

MA Credit Income Trust reported a strong half-year profit of $19.7 million, exceeding its return target, while successfully completing a $190.5 million capital raise and initiating a strategic buy-back to manage liquidity.

Imugene Limited reports a narrower half-year loss as it advances its promising azer-cel CAR T therapy with strong clinical results and FDA backing, supported by a $25 million capital raise.

Optiscan Imaging reports a sharp 43% drop in revenue and a 43% rise in losses for H1 FY26, driven by restricted research funding in key markets. The company bolsters its balance sheet with a $17.75 million capital raise to advance clinical studies and regulatory approvals.

Embark Early Education Limited delivered a robust 2025 financial performance, marked by significant revenue and EBITDA growth, while setting sights on expanding through a strategic takeover bid for Mayfield Childcare Limited.